Dose-Responsive Effect of Polydextrose on Whole Gut Transit Time (PDX-Transit)
This study is currently recruiting participants.
Verified March 2012 by Danisco
Sponsor:
Danisco
Collaborator:
Sprim Advanced Life Sciences
Information provided by (Responsible Party):
Danisco
ClinicalTrials.gov Identifier:
NCT01540669
First received: February 23, 2012
Last updated: November 13, 2012
Last verified: March 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of the study is to test the effect of polydextrose on whole gut transit time and gastrointestinal symptoms in a dose-responsive manner.
| Condition | Intervention |
|---|---|
|
Functional Constipation |
Dietary Supplement: Polydextrose, low dose Dietary Supplement: Polydextrose, medium dose Dietary Supplement: Polydextrose, high dose Dietary Supplement: Placebo powder |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Dose-ranging Efficacy of 2-week Polydextrose Supplementation on Whole Gut Transit Time and Gastrointestinal Symptoms in Adults With Functional Constipation: A Double-blind, Randomized, Placebocontrolled Trial |
Resource links provided by NLM:
Further study details as provided by Danisco:
Primary Outcome Measures:
- Whole gut transit time [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Patient assessment of constipation quality of life [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
- Patient assessment of constipation symptoms [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
- Bowel Function Index [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
- Adequate relief of constipation [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
- Bowel movement frequency [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
- Stool consistency [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
- Degree of straining [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
- Subjective assessment of bowel emptying [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
- Abdominal discomfort/bloating [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
- Overall product satisfaction [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
- Blood and urine safety analysis [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]
- Adverse events [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 184 |
| Study Start Date: | March 2012 |
| Estimated Study Completion Date: | September 2013 |
| Estimated Primary Completion Date: | May 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Polydextrose, low dose
Polydextrose, low dose
|
Dietary Supplement: Polydextrose, low dose
4g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
|
|
Active Comparator: Polydextrose, medium dose
Polydextrose, medium dose
|
Dietary Supplement: Polydextrose, medium dose
8g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
|
|
Active Comparator: Polydextrose, high dose
Polydextrose, high dose
|
Dietary Supplement: Polydextrose, high dose
12g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
|
|
Placebo Comparator: Placebo powder
Placebo powder
|
Dietary Supplement: Placebo powder
Placebo powder will be mixed with beverage and consumed once per day for 2 weeks
|
Detailed Description:
Given the promising, yet largely unsubstantiated, benefits of fiber supplementation, particularly polydextrose, on symptoms of functional constipation, the objective of this clinical trial is to evaluate the safety and effectiveness of 2-week supplementation of a proprietary polydextrose fiber product, in a dose-ranging fashion, on whole gut transit time and gastrointestinal symptoms in adults with functional constipation.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Age between 18 and 70 years
- Body mass index between 18.5 and 29.9 kg/m2 (encompasses normal weight and overweight)
- Meets the Rome III criteria for functional constipation as follows: (Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis):
Must meet 2 or more of the following criteria:
- Straining during at least 25% of defecations
- Lumpy or hard stools in at least 25% of defecations
- Sensation of incomplete evacuation for at least 25% of defecations
- Sensation of anorectal obstruction/blockage for at least 25% of defecations
- Manual maneuvers to facilitate at least 25% of defecations (e.g., digital evacuation, support of the pelvic floor)
Fewer than three defecations per week
- Loose stools are rarely present without the use of laxatives
- Insufficient criteria for irritable bowel syndrome
- Ability of the participant (in the investigator's opinion) to comprehend the full nature and purpose of the study including possible risks and side effects
- Consent to the study and willing to comply with study product and methods
- Willingness to maintain a stable diet throughout the study
- Consistent use and dose of chronic medication, if any, in the past 30 days
Exclusion Criteria:
- Major gastrointestinal complication (e.g. Crohn‟s disease, colitis, celiac disease)
- Febrile diverticulitis within 1 year of screening
- Pelvic floor dysfunction
- Prior abdominal surgery that in the opinion of the investigator may present a risk for the subject or confound study results
- Prior abdominal surgery of the following type: gastric bypass, lap band, colectomy, removal of gall bladder
- Clinically significant underlying systemic illness that may preclude the subject‟s ability to complete the trial or that may confound the study outcomes
- Any clinically relevant abnormalities in the physical examination or in laboratory variables before entry into the study
- Daily consumption of probiotics, prebiotics, fermented milk, and/or yogurt within 2 weeks of screening
- Laxative, fiber supplement, or other constipation medication (e.g. prokinetic drugs) use within 2 weeks of screening
- Antibiotic use within 1 month of enrollment
- Regular use of any drug or dietary supplement known to cause constipation (e.g. iron, opioids, sucralfate, misoprostol, 5-HT#- antagonists, antacids with magnesium or aluminum, or diarrhea medication)
- Anticipated major dietary or exercise changes during the study period
- Known allergies to any substance in the study product
- Pregnant or lactating female, or pregnancy planned during study period
- Eating disorder
- History of alcohol, drug, or medication abuse
- Participation in another study with any investigational product within 3 months of screening
- Investigator believes that the participant may be uncooperative and/or noncompliant and should therefore not participate in the study
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01540669
Contacts
| Contact: Silvia Lazzati | 02 45495838 | silvia.lazzati@sprim.com |
Locations
| Italy | |
| Istituto Clinico Humanitas | Recruiting |
| Milan, Italy, 20089 | |
| Contact: Silvio Danese, MD silvio.danese@humanitas.it | |
| Principal Investigator: Silvio Danese, MD | |
Sponsors and Collaborators
Danisco
Sprim Advanced Life Sciences
Investigators
| Principal Investigator: | Silvio Danese, MD | Istituto Clinico Humanitas |
More Information
No publications provided
| Responsible Party: | Danisco |
| ClinicalTrials.gov Identifier: | NCT01540669 History of Changes |
| Other Study ID Numbers: | Q-PRE-0111-CLI-007 |
| Study First Received: | February 23, 2012 |
| Last Updated: | November 13, 2012 |
| Health Authority: | Italy: Ethics Committee |
Keywords provided by Danisco:
|
constipation functional constipation polydextrose whole gut transit time |
Additional relevant MeSH terms:
|
Constipation Signs and Symptoms, Digestive Signs and Symptoms |
ClinicalTrials.gov processed this record on May 23, 2013